Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 5 | 2025 | 195 | 1.510 |
Why?
|
| Alzheimer Disease | 4 | 2026 | 1001 | 1.310 |
Why?
|
| Probability | 3 | 2019 | 82 | 1.220 |
Why?
|
| Computer Simulation | 4 | 2025 | 408 | 1.000 |
Why?
|
| Clinical Trials as Topic | 3 | 2026 | 259 | 0.940 |
Why?
|
| Cerebrovascular Disorders | 1 | 2025 | 43 | 0.900 |
Why?
|
| Health Status Disparities | 3 | 2025 | 719 | 0.790 |
Why?
|
| Treatment Outcome | 4 | 2025 | 1604 | 0.790 |
Why?
|
| Cardiovascular Diseases | 3 | 2025 | 749 | 0.770 |
Why?
|
| Research Design | 2 | 2022 | 385 | 0.730 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 375 | 0.690 |
Why?
|
| Hawaii | 11 | 2026 | 2011 | 0.680 |
Why?
|
| Malaria, Falciparum | 2 | 2022 | 90 | 0.670 |
Why?
|
| Survival Analysis | 2 | 2018 | 368 | 0.630 |
Why?
|
| Aging | 1 | 2025 | 783 | 0.620 |
Why?
|
| Medicaid | 2 | 2018 | 143 | 0.620 |
Why?
|
| HIV Infections | 7 | 2023 | 2586 | 0.610 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 115 | 0.610 |
Why?
|
| Antigens, Protozoan | 2 | 2022 | 74 | 0.570 |
Why?
|
| Antibodies, Protozoan | 2 | 2022 | 82 | 0.560 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 10 | 0.540 |
Why?
|
| Humans | 33 | 2026 | 43102 | 0.540 |
Why?
|
| Antiviral Agents | 1 | 2019 | 195 | 0.530 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 83 | 0.530 |
Why?
|
| Plasmodium falciparum | 2 | 2022 | 144 | 0.530 |
Why?
|
| Placenta | 1 | 2017 | 117 | 0.500 |
Why?
|
| Medicare | 3 | 2025 | 332 | 0.480 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 115 | 0.480 |
Why?
|
| Prognosis | 1 | 2019 | 861 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 310 | 0.470 |
Why?
|
| Disease Progression | 1 | 2018 | 667 | 0.460 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 193 | 0.460 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 310 | 0.450 |
Why?
|
| Huntington Disease | 3 | 2024 | 31 | 0.430 |
Why?
|
| Gene Expression | 1 | 2016 | 701 | 0.400 |
Why?
|
| Aged, 80 and over | 4 | 2026 | 2853 | 0.400 |
Why?
|
| Aged | 7 | 2026 | 8214 | 0.400 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 539 | 0.380 |
Why?
|
| Male | 16 | 2026 | 23409 | 0.370 |
Why?
|
| Female | 16 | 2026 | 24698 | 0.360 |
Why?
|
| Neurodegenerative Diseases | 2 | 2024 | 141 | 0.340 |
Why?
|
| Multivariate Analysis | 2 | 2025 | 638 | 0.340 |
Why?
|
| United States | 6 | 2025 | 5205 | 0.300 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 1234 | 0.270 |
Why?
|
| Retrospective Studies | 5 | 2026 | 2544 | 0.270 |
Why?
|
| Brain Concussion | 2 | 2025 | 36 | 0.260 |
Why?
|
| Censuses | 2 | 2023 | 28 | 0.260 |
Why?
|
| Regression Analysis | 2 | 2017 | 490 | 0.240 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 28 | 0.230 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 486 | 0.230 |
Why?
|
| Post-Concussion Syndrome | 1 | 2025 | 5 | 0.230 |
Why?
|
| Headache | 1 | 2025 | 21 | 0.230 |
Why?
|
| Athletic Injuries | 1 | 2024 | 26 | 0.210 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2025 | 70 | 0.210 |
Why?
|
| Athletes | 1 | 2024 | 62 | 0.210 |
Why?
|
| Patient Selection | 1 | 2026 | 205 | 0.210 |
Why?
|
| Sex Distribution | 1 | 2023 | 224 | 0.200 |
Why?
|
| Age Distribution | 1 | 2023 | 249 | 0.200 |
Why?
|
| Middle Aged | 8 | 2025 | 12222 | 0.180 |
Why?
|
| Malaria | 1 | 2022 | 90 | 0.180 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1063 | 0.180 |
Why?
|
| Family Practice | 1 | 2022 | 60 | 0.180 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2025 | 298 | 0.170 |
Why?
|
| Mitochondrial Membranes | 1 | 2021 | 41 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2023 | 169 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Peptides | 1 | 2024 | 372 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2022 | 146 | 0.160 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 26 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2022 | 139 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 60 | 0.160 |
Why?
|
| Biostatistics | 1 | 2019 | 10 | 0.160 |
Why?
|
| Adult | 7 | 2025 | 13872 | 0.160 |
Why?
|
| Adolescent | 3 | 2024 | 6081 | 0.150 |
Why?
|
| Double-Blind Method | 1 | 2019 | 317 | 0.150 |
Why?
|
| Receptors, Immunologic | 1 | 2019 | 73 | 0.150 |
Why?
|
| Students | 1 | 2024 | 626 | 0.140 |
Why?
|
| Infant | 2 | 2022 | 1175 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 116 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2019 | 92 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 247 | 0.140 |
Why?
|
| Endocrine System Diseases | 1 | 2018 | 16 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 37 | 0.140 |
Why?
|
| Empirical Research | 1 | 2017 | 8 | 0.140 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 173 | 0.140 |
Why?
|
| Cameroon | 1 | 2017 | 35 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 19 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 40 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2018 | 47 | 0.130 |
Why?
|
| Markov Chains | 1 | 2017 | 43 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2018 | 63 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 317 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 989 | 0.130 |
Why?
|
| Leukemia | 1 | 2017 | 54 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 279 | 0.130 |
Why?
|
| Young Adult | 4 | 2025 | 5080 | 0.130 |
Why?
|
| Risk Factors | 3 | 2023 | 3994 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 269 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2018 | 141 | 0.130 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 69 | 0.130 |
Why?
|
| Mitochondria | 1 | 2020 | 523 | 0.120 |
Why?
|
| Mutation | 1 | 2021 | 1177 | 0.120 |
Why?
|
| Quality of Life | 1 | 2020 | 616 | 0.120 |
Why?
|
| Comorbidity | 1 | 2018 | 737 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 549 | 0.110 |
Why?
|
| Monocytes | 3 | 2023 | 277 | 0.110 |
Why?
|
| RNA | 1 | 2016 | 266 | 0.110 |
Why?
|
| HIV-1 | 1 | 2020 | 755 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2018 | 1546 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3156 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 968 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2019 | 518 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 590 | 0.090 |
Why?
|
| Pregnancy | 1 | 2017 | 1772 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1766 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 760 | 0.090 |
Why?
|
| Child | 1 | 2018 | 3443 | 0.080 |
Why?
|
| Rats | 1 | 2016 | 3735 | 0.070 |
Why?
|
| Animals | 2 | 2024 | 16992 | 0.050 |
Why?
|
| Amyloid | 1 | 2024 | 65 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2023 | 30 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2024 | 80 | 0.050 |
Why?
|
| Guam | 1 | 2023 | 83 | 0.050 |
Why?
|
| Translating | 1 | 2023 | 18 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2023 | 18 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 76 | 0.050 |
Why?
|
| Veterans | 1 | 2025 | 210 | 0.050 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2022 | 34 | 0.050 |
Why?
|
| Communication Barriers | 1 | 2023 | 60 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 102 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 86 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2023 | 229 | 0.050 |
Why?
|
| Lipids | 1 | 2024 | 256 | 0.050 |
Why?
|
| Neopterin | 1 | 2022 | 13 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2022 | 23 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2022 | 46 | 0.050 |
Why?
|
| Alkynes | 1 | 2022 | 52 | 0.050 |
Why?
|
| Vietnam | 1 | 2022 | 62 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2022 | 47 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 74 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 259 | 0.040 |
Why?
|
| Faculty | 1 | 2022 | 105 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2023 | 263 | 0.040 |
Why?
|
| Universities | 1 | 2024 | 559 | 0.040 |
Why?
|
| Lipid Bilayers | 1 | 2021 | 57 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 29 | 0.040 |
Why?
|
| Glutathione | 1 | 2021 | 171 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2020 | 82 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 318 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 249 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1612 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 321 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 209 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2021 | 460 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 163 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.030 |
Why?
|